<div id="readability-page-1"><ul><li>Eli Lilly Posts Stellar Q3: Long-Term Upside Is Well in Play</li></ul><p>Eli Lilly and Company, Pfizer, Novo Nordisk A/S, 89BIO,  and Metsera are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and sell prescription drugs, vaccines, and related therapies. For investors, these stocks are often driven by clinical trial results, regulatory approvals, patent expirations and pricing pressures, which can create both significant upside potential and higher volatility compared with broader market sectors. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><h2>Eli Lilly and Company (LLY)</h2><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><ul><li>Got 1K to Invest? These 3 Stocks Are Still Attractive Buys</li></ul><p>Read Our Latest Research Report on LLY</p><h2>Pfizer (PFE)</h2><p>Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p><ul><li>Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead</li></ul><p>Read Our Latest Research Report on PFE</p><h2>Novo Nordisk A/S (NVO)</h2><p>Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.</p><p>Read Our Latest Research Report on NVO</p><h2>89BIO (ETNB)</h2><p>89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.</p><p>Read Our Latest Research Report on ETNB</p><h2>Metsera (MTSR)</h2><p>Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.</p><p>Read Our Latest Research Report on MTSR</p><h2>Read More</h2><ul><li>MarketBeat's Top Five Stocks to Own in November 2025</li><li>Shopify Pullback Sets Stage for 20% Rally to $200 Target</li><li>Roku's Profit Engine Roars to Life: Is the Rally Just Beginning?</li><li>Why Palantir Stock Fell After Another Strong Quarter</li><li>Intel's SambaNova Play Isn't an Acquisition, It's an Ambush</li><li>Why Roblox Stock Could Soar 75% After the Q3 Dip</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ETNB

<p>Eli Lilly, Pfizer, Novo Nordisk, 89BIO, and Metsera are highlighted as promising pharmaceutical stocks to watch, according to MarketBeat. These companies are involved in developing and marketing drugs and therapies, with their stock performance influenced by clinical trials and regulatory approvals. Eli Lilly has shown strong Q3 results, while Pfizer continues to expand its biopharmaceutical offerings. Novo Nordisk focuses on diabetes and obesity care, 89BIO targets liver diseases, and Metsera develops treatments for obesity. Investors are advised to monitor these stocks closely for potential opportunities.</p>

- Eli Lilly and Company, along with Pfizer, Novo Nordisk, 89BIO, and Metsera, are highlighted as key pharmaceutical stocks to monitor due to their recent high trading volumes.  
- The pharmaceutical sector is influenced by factors such as clinical trial outcomes, regulatory approvals, and pricing pressures, which can lead to significant volatility and investment opportunities.  
- Despite a Moderate Buy rating for Eli Lilly, analysts suggest that there are currently five other stocks that may present better investment prospects.

Promising Pharmaceutical Stocks Worth Watching - November 4th